Mostrar el registro sencillo del ítem
dc.contributor.author | Crabtree-Ramírez, B. | |
dc.contributor.author | Jenkins, C. | |
dc.contributor.author | Jayathilake, K. | |
dc.contributor.author | Carriquiry, G. | |
dc.contributor.author | Veloso, V. | |
dc.contributor.author | Padgett, D. | |
dc.contributor.author | Gotuzzo Herencia, José Eduardo | |
dc.contributor.author | Cortes, C. | |
dc.contributor.author | Mejía Cordero, Fernando Alonso | |
dc.contributor.author | McGowan, C.C. | |
dc.contributor.author | Duda, S. | |
dc.contributor.author | Shepherd, B.E. | |
dc.contributor.author | Sterling, T.R. | |
dc.date.accessioned | 2019-12-06T20:57:49Z | |
dc.date.available | 2019-12-06T20:57:49Z | |
dc.date.issued | 2019 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/7436 | |
dc.description.abstract | BACKGROUND: Tuberculosis (TB) diagnosis in human immunodeficiency virus (HIV) positive persons is difficult, particularly in resource-limited settings. The relationship between TB culture status and mortality in HIV-positive persons treated for TB is unclear. METHODS : We evaluated HIV-positive adults treated for TB at or after their first HIV clinic visit in Argentina, Brazil, Chile, Honduras, Mexico or Peru from 2000 to 2015. Anti-tuberculosis treatment included 2 months of isoniazid, rifampicin (RMP)/rifabutin (RBT), pyrazinamide 6 ethambutol, followed by continuation phase treatment with isoniazid + RMP/RBT. RESULTS : Of 759 TB-HIV patients, 238 (31%) were culture-negative, 228 (30%) had unknown culture status or did not undergo culture and 293 (39%) were culturepositive. The median CD4 at TB diagnosis was 96 (interquartile range 40-228); 636 (84%) received concurrent antiretroviral therapy (ART) and antituberculosis treatment. There were 123 (16%) deaths: 90/466 (19%) with TB culture-negative, unknown or not performed vs. 33/293 (11%) who were TB culturepositive (P=0.005). In Kaplan-Meier analysis, mortality in TB patients without culture-confirmed disease was higher (P=0.002). In a Cox model adjusted for age, sex, CD4, ART timing, disease site and stratified by study site, mortality in persons without culture-confirmed TB was not significantly increased compared to those with culture-positive TB (hazard ratio 1.39, 95%CI 0.89- 2.16, P = 0.15). CONCLUSION: Most HIV-positive patients treated for TB did not have culture-confirmed TB, and mortality tended to be higher in patients without culture-confirmed disease, although the association was not statistically different after adjusting for other variables. Accurate TB diagnosis in HIV-positive persons is crucial. | en_US |
dc.language.iso | eng | |
dc.publisher | International Union Against Tuberculosis and Lung Disease | |
dc.relation.ispartofseries | International Journal of Tuberculosis and Lung Disease | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | adult | en_US |
dc.subject | age distribution | en_US |
dc.subject | Anti-tuberculosis treatment | en_US |
dc.subject | Argentina | en_US |
dc.subject | Article | en_US |
dc.subject | bacterial growth | en_US |
dc.subject | bacterium culture | en_US |
dc.subject | CD4 lymphocyte count | en_US |
dc.subject | Chile | en_US |
dc.subject | cohort analysis | en_US |
dc.subject | controlled study | en_US |
dc.subject | Culture-negative tuberculosis | en_US |
dc.subject | disease association | en_US |
dc.subject | ethambutol | en_US |
dc.subject | female | en_US |
dc.subject | genetic heterogeneity | en_US |
dc.subject | Honduras | en_US |
dc.subject | human | en_US |
dc.subject | Human immunodeficiency virus and TB | en_US |
dc.subject | Human immunodeficiency virus infection | en_US |
dc.subject | isoniazid | en_US |
dc.subject | Latin America | en_US |
dc.subject | log rank test | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | Mexico | en_US |
dc.subject | mortality | en_US |
dc.subject | Peru | en_US |
dc.subject | priority journal | en_US |
dc.subject | probability | en_US |
dc.subject | pyrazinamide | en_US |
dc.subject | rifabutin | en_US |
dc.subject | rifampicin | en_US |
dc.subject | risk assessment | en_US |
dc.subject | tuberculosis | en_US |
dc.subject | World Health Organization | en_US |
dc.title | HIV-related tuberculosis: Mortality risk in persons without vs With culture-confirmed disease | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.5588/ijtld.18.0111 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.03.08 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.02.07 | |
dc.relation.issn | 1815-7920 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |